Introduction: Treatment of hereditary renal cell carcinoma (HRCC) requires a multidisciplinary approach that may involve medical oncologists, geneticists, genetic counsellors, and urologists. The objective of our survey was to obtain current and representative information about the use and perceived importance of genetic testing for HRCC in Canada. Methods: A self-administered web-based survey was provided to Canadian medical oncologists, geneticists, genetic counsellors, and urologists in collaboration with their respective associations. The survey was created through an iterative process in consultation with the Kidney Cancer Research Network of Canada and contained both quantitative and qualitative components. The survey was designed to be exploratory and results were compared across regions. Results: The overall response was low (6.6%). Of the respondents, 42%, 33%, 19%, 5% were genetic counsellors, urologists, medical oncologists and medical geneticists, respectively. Of the respondents, 62.7% described their practice as academic, and 37.3% described it as non-academic. Non-academic respondents tended to refer for genetic counselling less frequently than academic (48.6% vs. 67.2%). Most respondents believed that genetic testing for HRCC was available (82.8%), although 47.7% did not know which tests were available. This observation was consistent across provinces. Testing for Von Hippel-Lindau syndrome was given the highest priority among respondents. Limited provider knowledge, clinical guidelines, institutional funding, access, and poor coordination between disciplines were cited as barriers to testing. Interpretation: There is a need to increase provider knowledge of genetic testing for HRCC. These findings support the development of practice guidelines and national strategies to improve coordination of specialists and access to genetics services. Limitations of the present study include low survey response which did not allow for inferential analysis by geographic region or respondent specialty.
Introduction
Renal cell carcinoma (RCC) is the sixth most common cancer in men and the eighth most common in women. 1 In Canada there were 5900 new diagnoses and 1740 deaths from RCC in 2013. 2 Most are sporadic; however between 4% and 8% can be classified as hereditary. 3, 4 Some authors suggest that the true incidence of hereditary RCC (HRCC) may be much higher, but current estimates suffer from under diagnosis and underreporting. 5, 6 Several hereditary syndromes have been identified, the most common of which are Von HippelLindau (VHL), hereditary papillary RCC (HPRCC), hereditary leiomyomatosis and RCC (HLRCC), Birt-Hogg-Dube syndrome (BHD), and tuberous sclerosis complex (TSC). Each of these syndromes has distinctive presentation, associated conditions, aggressiveness, causal genes, and penetrance.
Treatment of hereditary RCC requires a multidisciplinary approach that may involve medical oncologists, dermatologists, geneticists, genetic counsellors, and urologists. The ability to provide a timely diagnosis and effective treatment plans is dependent on the availability of appropriate genetic testing for our patients. Additionally, genetic testing can have clinical utility for the relatives of patients, especially for conditions where screening has demonstrated efficacy. 7, 8 However, the current state of genetic testing for HRCC across Canada is unknown. It is essential to know the perceived clinical needs for genetic testing, gaps in availability between jurisdictions to identify areas for future research efforts and resource allocation. 8 Therefore, we conducted a 
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Hereditary RCC needs assessment survey national needs assessment survey to better understand the national and regional priorities for genetic testing of HRCC. . Each participating association was requested to distribute an invitation directly to their membership by email every 2 weeks for 6 consecutive weeks. The CDA was unable to comply with this protocol, but included an invitation to participate in the survey embedded in their monthly newsletter. As a result there were no responses from the CDA members and as such they were excluded from the study. The self-administered survey was available in French and English and was conducted using an internet based platform 9 from September 24, 2013 to December 13, 2013. The survey was designed and piloted to take 10 minutes. Post-survey analysis revealed that respondents took a mean of 11.28 minutes to complete the survey.
Methods

Development and design of questionnaire
Analysis
The survey platform allowed for both closed-and openended question types. Closed-ended questions were described for the population overall using percentages for categorical answers and mean with standard deviation (SD) for continuous data. Fewer responses were obtained from Saskatchewan, Manitoba, New Brunswick, Prince Edward Island, and Newfoundland. Therefore responses were grouped into 4 regions: Western Canada (British Columbia, Alberta, Saskatchewan, Manitoba), Ontario, Quebec and Eastern Canada (Newfoundland, Prince Edward Island, Nova scotia, New Brunswick). Answer choices were then grouped by region and compared with univariable statistics using SPSS version 20 (IBM Corp., Armonk, NY). This study was designed to be exploratory and therefore inferential statistics were not performed. Open-ended qualitative questions were summarized using an adaptation of qualitative description analytic strategies as described by Neergaard and colleagues. 10 Responses to open-ended questions were organized into responses with similar content. Raw themes were then extracted from each response. These raw themes were then grouped into common themes and subthemes, which captured the ideas expressed by the respondents.
Additional synthesis and refinement were carried out to more clearly present qualitative findings.
Results
Respondent characteristics
The overall response was low, with 136 respondents of 2054 invited (6.6% response rate). Healthcare providers whose primary location of practice was outside of Canada (n = 8) or who were not involved with patient care (n = 2) were excluded. Therefore, the total number of responses for analysis was 126 (6.1% overall). However, the sampling strategy inadvertently included retired members (n = 124), non-specialist members (n = 101) and members who practice outside of Canada (n = 169). When we adjusted for the study inclusion criteria, the overall response rate was 7.6%.
Of the respondents, 42%, 33%, 19%, 5% were genetic counsellors, urologists, medical oncologists and medical geneticists, respectively. The average number of years in practice was 10.6 ± 8.6. Geographically, 27% of respon-dents practiced in Western Canada, 43% in Ontario, 12% in Quebec and 18% in Eastern Canada (Fig. 1) 
Use of genetic testing and perceived availability
We asked respondents a series of questions designed to elicit the actual use of genetic testing for HRCC across Canada. Overall, 62% of respondents referred for genetic testing. There was an increase in the referral rate in Ontario relative to the other regions in Canada (71% vs. 51%, p < 0.04 (Fig. 2) . Similarly, academic practitioners reported increased referral for genetic testing (Fig. 3 ) over non-academic practitioners.
The actual use of genetic testing may be reflective of the perception of availability of genetic testing for HRCC. Of respondents, 82.8% believed that genetic testing for HRCC was available in their regions of practice. However, 47.7% did not know which tests were available. This observation was consistent across jurisdictions (Fig. 4) (Fig. 5) . A significant minority indicated that medical oncologists, urologists, and surgical oncologists should also be responsible for ordering genetic tests for HRCC. On open-ended questions, several respondents indicated that any practitioner who felt they had sufficient competence should order these tests.
Knowledge of indications
We asked respondents to select whether genetic testing should be ordered for a patient with a renal mass in 20 scenarios to assess knowledge base ( Table 1) . Thirteen of these scenarios were adapted directly from the CUA Consensus Guideline and as such were considered recognized indica- tions for genetic testing for HRCC. 11 Of these scenarios, a family history of a known HRCC-related syndrome was the most commonly recognized indication for genetic testing (79.7%-87.3%). Surprisingly, a minority of respondents recognized a renal mass of unusual histology as an indication for genetic testing (34.2%). Similarly, age ≤35 years, bilateral or multifocal renal masses, and concomitant pheochromocytoma were not recognized as indications for genetic testing by many respondents (34.4-44.3%). Additionally, a minority of respondents would order genetic testing for clinical situations in which genetic testing is not clearly recognized (Table 1) .
Limitations and barriers to genetic testing for HRCC
Two open-ended questions were used to elicit the perceived limitations and barriers to the use of genetic testing for HRCC. From qualitative analysis of these questions, 3 common themes emerged: (1) resources, (2) knowledge, and (3) clinical practice and perception. Within each common theme, several subthemes characterized the barriers and limitations to the use of genetic testing for HRCC ( Table 2) .
The respondents were asked to assess the impact of potential barriers on a 5 point scale (0-none, 1-little, 2-moderate, 3-high, 4-very high). A pre-defined list of 17 potential barriers was provided ( Table 3 ). The top 5 barriers identified as either high or very high impact were provider knowledge about availability, provider knowledge about clinical impact, provider knowledge about HRCC, lack of clinical guidelines and long wait times for genetics clinic referral.
Discussion
Availability and use
Our survey demonstrated that most respondents believed genetic testing was available in their jurisdiction (82.8%); however, a large proportion (41.2%) believed that patient access remained inadequate. This is similar to attitudes expressed in a survey of cancer physicians in Ontario likely to order or use molecular oncology testing conducted by Miller and colleagues in 2006. 12 In their survey, only 54% of physicians agreed that patients had access to molecular oncology testing according to standard of care. This difference may reflect increasing awareness among users of genetic testing over the past 8 years. However, our survey also suggests that provider awareness is limited to a general belief in access, but does not translate to knowledge of availability of specific tests. Among respondents, 47.7% reported not knowing which specific genetic tests were available in their region. This represents a clear limitation to patient access. We speculate that this is a reflection of limited regional guidelines, heterogeneous procedures to gain approval for Violette et al. Hereditary RCC needs assessment survey selective genetic testing, and a rapidly changing landscape for genetic testing across jurisdictions in Canada. The impact of uncertainty on delivery of healthcare is reflected in the heterogeneity of provincial regulations 13 and the use of genetic testing across regions. Adair and colleagues conducted a qualitative description of Canadian genetic healthcare providers from British Columbia, Alberta, Manitoba, Ontario, Quebec, and Nova Scotia.
14 They concluded that decision-making with regard to genetic testing in Canada was largely ad hoc and dependent on local priorities with regard to resource allocation. This observation was also reflected in our survey, in which the use of genetic testing for HRCC was considerably greater in Ontario than other regions (71% vs. 51%). We suggest that the increase in use of genetic testing in Ontario is a result of efforts to increase awareness and coordinate resources. For exam- 16 have been created to inform patients and family members. Consequently, this suggests that efforts to develop national treatment guidelines and funding strategies are warranted.
Technological advances in gene sequencing, with relative facility and decreased cost of next generation-sequencing are changing the landscape of genetic testing in Canada. 17 This increased availability combined with increased patient expectations of access 18 will result in an exponential increase in the demand for genetic testing in Canada. This poses a potential dilemma for providers and policy makers. Limited budgetary constraints and the number of trained specialist providers will not be adequate to cope with the demand for genetic testing. This tension may jeopardize patient care if an adequate model of healthcare delivery is not developed.
The management of HRCC can provide an ideal context in which to model systems of healthcare delivery in the age of personalized medicine. HRCC is diagnosable, with a limited number of currently available genetic tests and screening guidelines in Canada. As HRCC is less prevalent than other forms of cancer, the costs incurred for genetic testing are more manageable in a publically funded healthcare system. In this way healthcare delivery can be tailored to specific Canadian jurisdictions with limited financial impact. Lessons learned from devising equitable systems of care for HRCC can subsequently be extrapolated to more prevalent cancers and may represent significant cost-savings in the long term.
Gaps in knowledge
A recent Canadian consensus guideline has elaborated the indications for genetic testing. 11 The consensus was developed from a multidisciplinary group of medical geneticists, genetic counsellors, medical oncologists, and urologists and was intended to reflect the common practice of specialist practitioners in these areas. By design, our survey attempted to capture the practice patterns from a broader sampling of these same disciplines. Our results demonstrate an important gap between recommended practice and actual knowledge of the indications for genetic testing in HRCC. Furthermore, on analysis of qualitative questions, one of the most frequently sited barriers to the use of genetic testing for HRCC was the absence of recognized guidelines. This supports the need for efforts to further disseminate current guidelines and the need to develop additional guidelines focussing on algorithms for diagnosis and treatment of suspected HRCC. Similarly, formal knowledge translation activities should be integrated prospectively into guideline development.
Our survey revealed a significant gap in provider knowledge of indications for evaluation of HRCC. Young age of diagnosis is a well-established risk factor for HRCC, although there is no consensus age cut-off in the literature. [19] [20] [21] [22] [23] Shuch and colleagues recently evaluated the age distribution of RCC from the SEER-17 (Surveillance, Epidemiology, and End Results) registry and the Hereditary Kidney cancer registry of the National Cancer Institute to define a specific age threshold for genetic testing. 6 The authors found the highest sensitivity and specificity corresponded to an age threshold of ≤46 years. The CUA consensus guideline cut-off of ≤45 years is in accord with these findings. 11 To gather a broader consensus from Canadian practitioners, our survey divided age into 3 categories (≤35, 35-65, >65 years). Our hypothesis was that the younger age category would be most clearly identified as an indication for testing. Surprisingly, 34% of respondents did not consider age ≤35 years an indication for testing, while 54% would still consider genetic testing in patients over 65. Similarly, other accepted indications for genetic testing include patients with tumours that are bilateral, multifocal, or of unusual histology. In contrast to our expectation, only 59%, 58%, and 35% of respondents indicated that they would order genetic testing in these circumstances, respectively. This result indicates a significant discrepancy between the Canadian Consensus Guideline and common practice. As such, this reveals the need for greater efforts toward provider education and dissemination of guidelines.
With many advances in personalized medicine on the horizon, one can expect the knowledge of the genetic contribution to many known cancers to increase exponentially. Some authors suggest that up to 60% of patients diagnosed with sporadic RCC have a hereditary predisposition. 4 Likewise the complexity of tumour heterogeneity among RCC is becoming increasingly understood. [24] [25] [26] Although this heterogeneity poses a challenge to biomarker development, tailored therapies for somatic RCC are increasingly dependent on underlying genetic makeup of the tumours involved. 27, 28 Therefore it is critical to adequately support screening programs for HRCC; efforts to optimize care for these patients play an important role in advancing our understanding of the larger population with sporadic RCC. 24 
Perceived barriers
Barriers to genetic testing were assessed using both qualitative and quantitative methods in our survey. Qualitatively, 3 common themes emerged from open-ended questions: (1) resources, (2) knowledge, and (3) clinical practice and perception (Table 2) . Quantitatively, the most commonly identified barriers to the use of genetic testing were provider knowledge about availability (67%), clinical impact (65%), HRCC Hereditary RCC needs assessment survey (64%), lack of guidelines (55%), and wait times for genetic clinic referral (41%). To our knowledge no other survey has been conducted to identify the barriers to the use of genetic testing specifically for patients with HRCC. Research regarding barriers to genetic testing and personalized medicine in other contexts has drawn similar conclusions.
Limited resources, lack of funding for genetics programs, access to genetic services, and cost of testing have been identified as key barriers in several contexts. Among breast cancer patients in the United States, out-of-pocket costs for testing combined with poor reimbursement has resulted in postponed testing and delayed treatment decisions. 29 This factor may apply to the Canadian healthcare setting for tests that are not reimbursed, which varies by province. Among patients at risk for Huntington's disease, financial burden and opportunity costs of testing and time taken for appointments were identified as deterrents to genetic testing in British Columbia. 30 Weldon and Hawkins 29,30 also discuss difficulties with timing and inflexibility of the testing process as additional barriers that limit access and utility of genetic testing. Increasing costs of healthcare and limited perception of benefit are barriers to finding adequate funding models for genetic testing. 31 This is exacerbated by a shortage of trained genetic professionals and a lack of efficient clinical care delivery models. 31 Specific to kidney cancer, lack of knowledge about HRCC, the availability and benefits of testing, and treatment options for patients with positive testing further impair the delivery of genetic services. In a best-worst scaling experiment, physicians ranked the relative importance of factors that affect the decision to integrate genetic testing into their practice. The most important factor was type of test and its ability to prognosticate followed by physician training and availability of guidelines. These factors were considered more important than professional fees or the cost of genetic tests. 32 Several authors have identified a lack of knowledge and absence of guidelines as important barriers to establishing a coordinated system of referral and interpretation for genetic testing. 12, 31, 33 We believe that, in addition to developing guidelines, appropriate knowledge translation activities are essential to improving provider knowledge about genetic testing.
Lastly, the current clinical practice and perception of genetic testing poses a systemic limitation to patient access. Respondents of our survey reported that lack of coordination between specialists and a need for more subspecialisation were important barriers in the care of patients with HRCC. Some respondents suggested that creating regional subspecialty centres for HRCC could improve access. This finding is similar to that of Weldon and colleagues, who identified poor timing of testing as a barrier to clinical utility. 29 Testing can be time-consuming and test results
were not necessarily available when treatment decisions needed to be made. 29 Likewise Hamilton and colleagues performed an interview-based study of 5 specialities within the Veterans Administration facilities to assess the factors influencing organizational adoption and implementation of clinical genetic services. 34 They identified multiple barriers similar to those identified in our study. In addition, they identified that genetic testing had limited compatibility with some disciplines of medicine, such as cardiology and primary care, but high compatibility with neurology and oncology. Overall, the sites with successful genetics services had knowledgeable clinicians interested in developing services and organizational-level facilitators to streamline the test-ordering process. On an organizational level, a different approach has been adopted in Alberta. Alberta has established a centralized process for requesting genetic testing that is not otherwise available. This approach seems to have resulted in improved consistency of testing and a costsavings, but may have resulted in reduced access for some patients. 35 Out-of-province/country testing was identified as a barrier by respondents of our survey; perhaps a nationally centralized approach to ordering and conducting less common genetic testing is warranted. This would increase volumes, which may decrease costs. A nationally centralized approach could also assist in providing equal access across provinces in accord with The Canada Health Act.
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Conclusion and practice implications
Our study addresses an important gap regarding the use, provider knowledge, and perceptions of genetic testing for HRCC in Canada. We have identified a significant need to increase provider knowledge of genetic testing for HRCC. These findings support the development of practice guidelines and national strategies to improve the coordination of specialists and access to genetics services. We believe that HRCC provides an ideal context within which to develop these strategies.
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